End Stage Renal Failure on Dialysis Clinical Trial
Official title:
Blood Volume Monitoring Guided Ultrafiltration Biofeedback on Reduction of Intra-dialytic Hypotensive Episodes in Hemodialysis: A Randomized Cross Over Study
As kidney function declines, the ability to maintain water balance is impaired and is most
often treated with hemodialysis. The removal of excess water in hemodialysis often leads to
a sudden drop of blood pressure and causes symptoms of dizziness, light-headedness,
cramping, and chest pain. This sudden drop in blood pressure has been linked with
complications of heart attacks, strokes and even death. Research has focused on different
ways to prevent dangerous drops in blood pressure during hemodialysis. One way is the use of
blood volume monitoring biofeedback technology to monitor the patient's relative blood
volume and automatically reduce the amount of fluid that is being removed when the blood
volume is low to prevent the drop in blood pressure from occurring. This type of biofeedback
device is currently available on some hemodialysis machines and while this approach
appealing, it is not clear how effective this form of biofeedback is in preventing the drops
in blood pressure.
We plan to determine if the use of biofeedback based on the changes in the patient's blood
volume will reduce the number of sudden drops in blood pressure that occur during
hemodialysis. To do this, we will compare patients treated with this technology to current
hemodialysis practices and follow them for important adverse outcomes. The result of
interest will be the frequency of hemodialysis sessions complicated by a sudden symptomatic
drop in blood pressure. We also plan to monitor the amount of water in the different body
compartments, blood pressure, blood pressure medication use, markers of heart function, and
patient symptoms and quality of life.
We hope that by providing information on this technology we can reduce the sudden drops in
blood pressure in hemodialysis, the associated rates of serious disease or death, and
improve patient quality of life.
This is a 22 week parallel group, randomized crossover trial to determine the effect of blood volume monitoring, BVM, guided ultrafiltration (UF) biofeedback on symptomatic intradialytic hypotension (IDH) episodes amongst IDH prone patients. The first part of the study (Part 1 - Run-In/Dialysis Optimization Phase), eligible patients will undergo a four-week run-in phase. During this period all patients will undergo a comprehensive clinical assessment including, clinical weight assessment, anti-hypertensive medication review, and dialysis prescription standardization. At the end of the run-in phase, patients that still meet eligibility criteria will enter the randomized cross-over phase. In part 2 (Randomized Cross-Over Phase), patients are randomized to regular best clinical practice hemodialysis, HD (without BVM-guided UF biofeedback; control arm) or to BVM-guided UF biofeedback (intervention arm) for an 8 week period. This will be followed by a two-week washout phase and then patients will be crossed over for a second 8-week phase. The study will be conducted and reported following the Consolidated Standards of Reporting Trials (CONSORT) 2010 guidelines. ;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04103177 -
Physical Activity in Haemodialysis Patients: a Feasibility Study
|
N/A | |
Completed |
NCT01561118 -
DiaSport - Endurance-orientated Training Program With Children and Adolescents on Maintenance Hemodialysis
|
N/A | |
Withdrawn |
NCT03645720 -
The Prognosis of Graft Using Plastic Cannula in Hemodialysis
|
N/A | |
Active, not recruiting |
NCT02598635 -
Effects of Cholecalciferol on Osteoprotegerin Levels in Patients on Peritoneal Dialysis
|
Phase 4 | |
Terminated |
NCT01643733 -
Study on Fistuloplasty Using Flow Measurement Guidance
|
N/A | |
Not yet recruiting |
NCT03169400 -
Theranova Dialyzer and Chronic Kidney Disease - Mineral Bone Disorder (CKD-MBD)
|
N/A | |
Completed |
NCT02439697 -
A Cohort Study of Conversion From Aranesp® to NESP® for the Treatment of Anemia in Dialysis Patients
|
N/A | |
Completed |
NCT02063490 -
Nurse-led Intervention to Improve Phosphate Binder Adherence
|
N/A | |
Completed |
NCT04106310 -
Theranova vs High-flux HD Comparison
|
N/A | |
Recruiting |
NCT06056102 -
CAR-T Cell Therapy for Desensitization in Kidney Transplantation
|
Phase 1 | |
Completed |
NCT04698512 -
MAgicTouchâ„¢ Intervention Leap for Dialysis Access (MATILDA) Trial
|
||
Completed |
NCT02819011 -
OHI--Randomized Control Trial to Evaluate Efficacy, Acceptability, and Perception of Benefit of an Innovative Custom AFO
|
Phase 2 | |
Completed |
NCT02484118 -
Hemodialysis Blood Flow and Urea Clearance
|
N/A | |
Enrolling by invitation |
NCT01641757 -
Effect of Non-Surgical Periodontal Therapy on Serum Albumin Levels of Patients on Maintenance Hemodialysis Therapy,
|
Phase 2 | |
Completed |
NCT03172039 -
Antimicrobial Use and Stewardship in an Outpatient Hemodialysis Unit
|
N/A | |
Completed |
NCT03897231 -
Prevalence of Non-adherence to Medication Among Patients on Chronic Hemodialysis
|
||
Withdrawn |
NCT03145662 -
High Pressure Balloon vs Cutting Balloon
|
N/A | |
Completed |
NCT02621918 -
The Effects of Exercise in End-stage Renal Disease Patients Undergoing Hemodialysis
|
N/A | |
Completed |
NCT01356615 -
Low Molecular Weight Heparin for Hemodialysis Anticoagulation
|
N/A | |
Terminated |
NCT01033357 -
Safety Study of the Vascular Wrap Paclitaxel-Eluting Mesh for Hemodialysis Vascular Access
|
N/A |